Navin Reddy
Psychiatry · Washington, DCNPI 1487818670
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,477 and has fallen 74.5% since, to $376 in 2025. Among psychiatry clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$524
- Lundbeck LLC$327
- Indivior Inc.$299
- Shire North American Group Inc$212
- Otsuka America Pharmaceutical, Inc.$174
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$159
- plus $709 from 11 others
What the payments were for
- Food & beverage$2,34398%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $524 |
| Lundbeck LLC | 20 | $327 |
| Indivior Inc. | 23 | $299 |
| Shire North American Group Inc | 10 | $212 |
| Otsuka America Pharmaceutical, Inc. | 9 | $174 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $159 |
| Bausch Health US, LLC | 8 | $133 |
| Avanir Pharmaceuticals, Inc. | 5 | $105 |
| Sunovion Pharmaceuticals Inc. | 6 | $91 |
| Alkermes, Inc. | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| CSL Behring | 1 | $40 |
| Neos Therapeutics, LP | 2 | $34 |
| Adlon Therapeutics L.p. | 2 | $34 |
| Titan Pharmaceuticals, Inc. | 2 | $26 |
| Johnson & Johnson | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,403 in reported general payments places this provider in the 90th percentile of 226 psychiatry providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $13,406 |
| Diazepam | 15 | $77 |
| Quetiapine Fumarate | 18 | $76 |
| Zolpidem Tartrate | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Washington
- Ikechi NnawuchiWashington$624K
- James GordonWashington$20K
- Thomas MellmanWashington$19K
- Tony GoreWashington$11K
- Dwight KingWashington$10K
- Igor VolkovWashington$10K
- Joel KleinmanWashington$8K
- Vivienne GomesWashington$6K
- Irfan SaeedWashington$6K
- Arda KasaciWashington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.